← All trials
NCT04349228
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2020
- Primary completion
- Jul 15, 2020
- Completion date
- Jul 15, 2020
- First posted
- Apr 16, 2020
- Last posted
- Apr 20, 2020
- Enrollment
- 530
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Abderrahmane Mami HospitalLead sponsor
- Abderrahmane Mami HospitalReponsible party - principal investigator
- Abderrahmane Mami HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.